Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded enzyme and transporter findings by polarity

Inspect every admitted source sentence for an exact medicine, enzyme or transporter, and recorded role, with assertions, denials, and unresolved polarity counted separately.

What this does not mean: This is not a drug interaction checker. A denial applies only to the named medicine, role, counterparty, conditions, and source sentence; it is not proof of no interaction and is not dosing or treatment advice.
Public rows
8,404
Generated
Schema version
1.3.0

Coverage

What this run contains

Medicine–counterparty–role groups
8,404
Source sentence records
20,358
Asserted sentences
4,700
Denied sentences
7,494
Polarity not recorded
8,164
Medicines represented
755
Counterparties represented
36
Corpus records considered
9,855
All corpus records were checked; a record without a documented counterparty cannot produce a row in this projection.
inducer groups
617
inhibitor groups
3,131
not_recorded groups
3,074
substrate groups
1,582

Method

How the rows were made

  1. A deterministic parser reads recorded FDA-label excerpts for named enzymes and transporters.
  2. A mention is admitted only when the stored excerpt contains the recorded counterparty, allowing letter-case differences only.
  3. Every admitted mention is grouped by exact medicine slug, recorded counterparty spelling, and exact role. A missing role remains NOT_RECORDED rather than being assigned to another group.
  4. Each sentence carries the exact source version and effective date when recorded; the API serializes null and the page says not recorded when either is absent.
  5. The API paginates groups. Within each returned group, sentences is the complete untruncated list used by the three polarity counts.

Limits

Read these before using a row

  • A recorded role is a mechanistic statement copied from a descriptive label section. It is not a clinical interaction, and nothing in this dataset describes what happens when a person is exposed to two medicines at once.
  • This dataset holds no relation between one medicine and another. Counts are per counterparty; the medicines naming a counterparty are listed with their sentences and are never paired, ranked against each other or compared.
  • ICH M12 states that no potency classification system exists for transporters or for non-CYP enzymes, so no strong, moderate or weak vocabulary is applied to any counterparty here. The tallies count records, not strength.
  • A counterparty with a high count is one that labels document often. Documentation frequency is not importance: US labelling asks for some enzymes to be characterised far more routinely than others, and that requirement is part of what these counts measure.
  • 40.1% of admitted mentions carry no role. The sentence named more than one role and the parser left the question open rather than attaching a guess, so a role tally is a count of sentences that settled the question, not of medicines for which it is settled.
  • Recorded spellings are counted separately and never merged. P-GP, PGP and P-GLYCOPROTEIN are three entries in this dataset because they are three strings in the corpus; whether they name one thing is a question for a person, and prefix relationships are reported as questions rather than resolved.
  • 9088 of 9855 records name no enzyme or transporter at all. That is an absence of recorded text in the sources fetched for those records. It is neither reassurance nor alarm about the medicines concerned.
  • 20358 of 20358 admitted mentions come from records the deterministic label parser produced, where no person chose the value or wrote its measurement context. The sentence is stored with each one so a reader can check it.
  • The uniform reference for concentration allocates the same 20358 mentions over the same 36 counterparties by chance. Labels are not written that way, so the reference shows only that the observed spread is not a consequence of how many mentions there are.
  • The public rows enumerate documentation about one medicine and one named counterparty. They never create medicine-to-medicine pairs and cannot answer whether two medicines interact.
  • A NOT_RECORDED role or polarity remains unresolved. It is never folded into an assertion or a denial.
  • Each returned group includes every admitted source sentence for checking, but the full source document remains authoritative.

Provenance

Source examples

Abacavir · CYP3A4 inhibitor

2 asserted · 2 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.

Abacavir · BCRP substrate

0 asserted · 4 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Based on in vitro study results, abacavir at therapeutic drug exposures is not expected to affect the pharmacokinetics of drugs that are substrates of the following transporters: organic anion transporter polypeptide (OATP)1B1/3, breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp), organic cation transporter (OCT)1, OCT2, or multidrug and toxic extrusion protein (MATE)1 and MATE2-K.

Abacavir · CYP2C9 not_recorded

0 asserted · 0 denied · 2 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Abacavir did not inhibit or induce other CYP enzymes (such as CYP2C9, or CYP2D6).

Artifact used for this view: data/agents/current/enzyme-and-transporter-documentation.json. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
medicineNamestringRecorded medicine name; not normalized for display style.
counterpartystringThe exact recorded counterparty spelling.
rolestringSUBSTRATE, INHIBITOR, INDUCER, or NOT_RECORDED when the sentence did not settle one role.
assertedCountnumberSentence records whose polarity is ASSERTED.
deniedCountnumberSentence records whose polarity is NEGATED.
polarityNotRecordedCountnumberSentence records for which the parser did not settle assertion or denial.
sentencessentence[]Every admitted sentence for this group, with polarity, section, source identity, source version/effective date or explicit absence, retrieval date, and exact excerpt. The list is not truncated.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact recorded role.

Exact recorded counterparty spelling.

Clear

Showing 3,271–3,280 of 8,404 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 3271

    Medicine slug
    fosphenytoin
    Medicine name
    Fosphenytoin
    Enzyme or transporter
    CYP2C9
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    8
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:d4c36fad-0ba2-4cd4-9c5e-dcf843f38a5a (opens source in a new tab)

      Fosphenytoin label

      Version not recorded · Effective date not recorded

      Metabolism Phenytoin derived from administration of CEREBYX is extensively metabolized in the liver by the cytochrome P450 enzyme CYP2C9 and to a lesser extent by CYP2C19.
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:d4c36fad-0ba2-4cd4-9c5e-dcf843f38a5a (opens source in a new tab)

      Fosphenytoin label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Phenytoin derived from administration of CEREBYX is extensively metabolized in the liver by the cytochrome P450 enzyme CYP2C9 and to a lesser extent by CYP2C19 [see Drug Interactions (7.1 , 7.2) ] .
    3. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:d4c36fad-0ba2-4cd4-9c5e-dcf843f38a5a (opens source in a new tab)

      Fosphenytoin label

      Version not recorded · Effective date not recorded

      Metabolism Phenytoin derived from administration of CEREBYX is extensively metabolized in the liver by the cytochrome P450 enzyme CYP2C9 and to a lesser extent by CYP2C19.
    4. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:d4c36fad-0ba2-4cd4-9c5e-dcf843f38a5a (opens source in a new tab)

      Fosphenytoin label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Phenytoin derived from administration of CEREBYX is extensively metabolized in the liver by the cytochrome P450 enzyme CYP2C9 and to a lesser extent by CYP2C19 [see Drug Interactions (7.1 , 7.2) ] .
    5. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:d4c36fad-0ba2-4cd4-9c5e-dcf843f38a5a (opens source in a new tab)

      Fosphenytoin label

      Version not recorded · Effective date not recorded

      Figure 1 12.5 Pharmacogenomics CYP2C9 activity is decreased in individuals with genetic variants such as the CYP2C9*2 and CYP2C9*3 alleles.
    6. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:d4c36fad-0ba2-4cd4-9c5e-dcf843f38a5a (opens source in a new tab)

      Fosphenytoin label

      Version not recorded · Effective date not recorded

      Other decreased or nonfunctional CYP2C9 alleles may also result in decreased clearance of phenytoin (e.g., *5, *6, *8, *11).
    7. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:d4c36fad-0ba2-4cd4-9c5e-dcf843f38a5a (opens source in a new tab)

      Fosphenytoin label

      Version not recorded · Effective date not recorded

      The prevalence of the CYP2C9 poor metabolizer phenotype is approximately 2–3% in the White population, 0.5–4% in the Asian population, and <1% in the African American population.
    8. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:d4c36fad-0ba2-4cd4-9c5e-dcf843f38a5a (opens source in a new tab)

      Fosphenytoin label

      Version not recorded · Effective date not recorded

      The CYP2C9 intermediate phenotype prevalence is approximately 35% in the White population, 24% in the African American population, and 15–36% in the Asian population [see Warnings and Precautions (5.4) and Use in Specific Populations (8.7) ] .

  2. Projected row 3272

    Medicine slug
    fostamatinib
    Medicine name
    Fostamatinib
    Enzyme or transporter
    BCRP
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      R406 can inhibit CYP3A4 and BCRP, and can induce CYP2C8 activity.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      R406 can inhibit CYP3A4 and BCRP, and can induce CYP2C8 activity.

  3. Projected row 3273

    Medicine slug
    fostamatinib
    Medicine name
    Fostamatinib
    Enzyme or transporter
    BCRP
    Role
    SUBSTRATE
    Asserted sentences
    2
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      BCRP substrate : Concomitant use of rosuvastatin (single dose 20 mg) with 100 mg twice daily TAVALISSE increased rosuvastatin AUC by 95% and C max by 88%.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      BCRP substrate : Concomitant use of rosuvastatin (single dose 20 mg) with 100 mg twice daily TAVALISSE increased rosuvastatin AUC by 95% and C max by 88%.
    3. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      R406 is a substrate of P-gp but not of other major transporters (OAT1/3, OCT2, OATP1B1/3, MRP2, and BCRP).
    4. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      R406 is a substrate of P-gp but not of other major transporters (OAT1/3, OCT2, OATP1B1/3, MRP2, and BCRP).

  4. Projected row 3274

    Medicine slug
    fostamatinib
    Medicine name
    Fostamatinib
    Enzyme or transporter
    CYP2C8
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    4
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Clinical Pharmacology Studies No significant interactions were seen with concomitant use of TAVALISSE with the following drugs: methotrexate (OAT1/3 transporters), midazolam (CYP3A4 substrate), microgynon (ethinyl estradiol and levonorgestrel), warfarin, pioglitazone (CYP2C8 substrate) and ranitidine (H2-antagonist that increases gastric pH).
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      R406 can inhibit CYP3A4 and BCRP, and can induce CYP2C8 activity.
    3. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Clinical Pharmacology Studies No significant interactions were seen with concomitant use of TAVALISSE with the following drugs: methotrexate (OAT1/3 transporters), midazolam (CYP3A4 substrate), microgynon (ethinyl estradiol and levonorgestrel), warfarin, pioglitazone (CYP2C8 substrate) and ranitidine (H2-antagonist that increases gastric pH).
    4. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      R406 can inhibit CYP3A4 and BCRP, and can induce CYP2C8 activity.

  5. Projected row 3275

    Medicine slug
    fostamatinib
    Medicine name
    Fostamatinib
    Enzyme or transporter
    CYP3A4
    Role
    INDUCER
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      CYP3A4 inducer : Concomitant use of rifampicin (600 mg once daily for 8 days) with a single dose of 150 mg TAVALISSE decreased R406 AUC by 75% and C max by 59% .
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      CYP3A4 inducer : Concomitant use of rifampicin (600 mg once daily for 8 days) with a single dose of 150 mg TAVALISSE decreased R406 AUC by 75% and C max by 59% .

  6. Projected row 3276

    Medicine slug
    fostamatinib
    Medicine name
    Fostamatinib
    Enzyme or transporter
    CYP3A4
    Role
    INHIBITOR
    Asserted sentences
    4
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      Effect of Other Drugs on TAVALISSE Strong CYP3A4 inhibitor : Concomitant use of ketoconazole (200 mg twice daily for 3.5 days) with a single dose of 80 mg TAVALISSE (0.53 times the 150 mg dosage) increased R406 AUC by 102% and C max by 37%.
    2. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      Moderate CYP3A4 Inhibitor : Concomitant use of verapamil (80 mg three times daily for 4 days) with a single dose of 150 mg TAVALISSE increased R406 AUC by 39% and C max by 6% .
    3. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      Effect of Other Drugs on TAVALISSE Strong CYP3A4 inhibitor : Concomitant use of ketoconazole (200 mg twice daily for 3.5 days) with a single dose of 80 mg TAVALISSE (0.53 times the 150 mg dosage) increased R406 AUC by 102% and C max by 37%.
    4. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      Moderate CYP3A4 Inhibitor : Concomitant use of verapamil (80 mg three times daily for 4 days) with a single dose of 150 mg TAVALISSE increased R406 AUC by 39% and C max by 6% .

  7. Projected row 3277

    Medicine slug
    fostamatinib
    Medicine name
    Fostamatinib
    Enzyme or transporter
    CYP3A4
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    8
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      R406 is extensively metabolized, primarily through pathways of CYP450-mediated oxidation (by CYP3A4) and glucuronidation (by UDP glucuronosyltransferase [UGT]1A9).
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Clinical Pharmacology Studies No significant interactions were seen with concomitant use of TAVALISSE with the following drugs: methotrexate (OAT1/3 transporters), midazolam (CYP3A4 substrate), microgynon (ethinyl estradiol and levonorgestrel), warfarin, pioglitazone (CYP2C8 substrate) and ranitidine (H2-antagonist that increases gastric pH).
    3. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      CYP3A4 and UGT1A9 are involved in the metabolism of R406.
    4. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      R406 can inhibit CYP3A4 and BCRP, and can induce CYP2C8 activity.
    5. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      R406 is extensively metabolized, primarily through pathways of CYP450-mediated oxidation (by CYP3A4) and glucuronidation (by UDP glucuronosyltransferase [UGT]1A9).
    6. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Clinical Pharmacology Studies No significant interactions were seen with concomitant use of TAVALISSE with the following drugs: methotrexate (OAT1/3 transporters), midazolam (CYP3A4 substrate), microgynon (ethinyl estradiol and levonorgestrel), warfarin, pioglitazone (CYP2C8 substrate) and ranitidine (H2-antagonist that increases gastric pH).
    7. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      CYP3A4 and UGT1A9 are involved in the metabolism of R406.
    8. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      R406 can inhibit CYP3A4 and BCRP, and can induce CYP2C8 activity.

  8. Projected row 3278

    Medicine slug
    fostamatinib
    Medicine name
    Fostamatinib
    Enzyme or transporter
    CYP3A4
    Role
    SUBSTRATE
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      Effect of TAVALISSE on Other Drugs CYP3A4 substrate: Concomitant use of simvastatin (single dose 40 mg) with 100 mg twice daily TAVALISSE increased simvastatin AUC by 64% and C max by 113% and simvastatin acid AUC by 64% and C max by 83%.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      Effect of TAVALISSE on Other Drugs CYP3A4 substrate: Concomitant use of simvastatin (single dose 40 mg) with 100 mg twice daily TAVALISSE increased simvastatin AUC by 64% and C max by 113% and simvastatin acid AUC by 64% and C max by 83%.

  9. Projected row 3279

    Medicine slug
    fostamatinib
    Medicine name
    Fostamatinib
    Enzyme or transporter
    OAT1
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Clinical Pharmacology Studies No significant interactions were seen with concomitant use of TAVALISSE with the following drugs: methotrexate (OAT1/3 transporters), midazolam (CYP3A4 substrate), microgynon (ethinyl estradiol and levonorgestrel), warfarin, pioglitazone (CYP2C8 substrate) and ranitidine (H2-antagonist that increases gastric pH).
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Clinical Pharmacology Studies No significant interactions were seen with concomitant use of TAVALISSE with the following drugs: methotrexate (OAT1/3 transporters), midazolam (CYP3A4 substrate), microgynon (ethinyl estradiol and levonorgestrel), warfarin, pioglitazone (CYP2C8 substrate) and ranitidine (H2-antagonist that increases gastric pH).

  10. Projected row 3280

    Medicine slug
    fostamatinib
    Medicine name
    Fostamatinib
    Enzyme or transporter
    OAT1
    Role
    SUBSTRATE
    Asserted sentences
    0
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      R406 is a substrate of P-gp but not of other major transporters (OAT1/3, OCT2, OATP1B1/3, MRP2, and BCRP).
    2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:21149cc3-049b-43e2-b141-c9499160556c (opens source in a new tab)

      Fostamatinib label

      Version not recorded · Effective date not recorded

      R406 is a substrate of P-gp but not of other major transporters (OAT1/3, OCT2, OATP1B1/3, MRP2, and BCRP).

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/enzyme-transporter-negatives?limit=10&offset=3270

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
role
Exact recorded role.Values: INDUCER, INHIBITOR, NOT_RECORDED, SUBSTRATE
counterparty
Exact recorded counterparty spelling.
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy
Enzyme and transporter findings | RNAWiki